ERCC4

Across TCGA pan-cancer cohorts, ERCC4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ERCC4 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ERCC4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ERCC4 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

GBM, HNSC, and PDAC are the cancer types where ERCC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.551	0.213	.016	6	view →
HNSC	DFS	Median	III,IV	0.851	0.695	.013	5	view →
PDAC	DFS	Median	III,IV	0.755	0.304	.003	5	view →
LSCC	DFS	Tertile	II,III,IV	0.802	0.530	.020	5	view →
LUAD	DFS	Median	III,IV	0.687	0.364	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ERCC4–GBM (OS)

Open the GBM breakdown →